Loading
Paris oncologist who led LMS-04, the trial that showed doxorubicin plus trabectedin lengthens survival in advanced leiomyosarcoma compared with doxorubicin alone.
Patricia Pautier is a medical oncologist at Gustave Roussy who treats sarcomas and gynaecological cancers. She was first author of the 2022 Lancet Oncology report of the French Sarcoma Group LMS-04 trial, in which doxorubicin plus trabectedin followed by trabectedin maintenance improved progression-free survival compared with doxorubicin alone as first-line treatment for metastatic or unresectable leiomyosarcoma; the 2024 update showed an overall survival gain.
| Title | Journal | Year |
|---|---|---|
| LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma | The Lancet Oncology | 2022 |
Shares Leiomyosarcoma, Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma, Retroperitoneal sarcoma, Leiomyosarcoma, Soft tissue sarcoma of the extremity (localised and advanced).
Shares Retroperitoneal sarcoma, Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.